close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Clearmind Medicine Inc.

< Previous 1 2 3 4 Next >
News headline image
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Applies to Cease Being a Reporting Issuer in Canada
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine CEO Issues Letter to Shareholders
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine Completed Type A Meeting with the FDA
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
News headline image
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today